Pharmaniaga

Pharmaniaga Berhad

Type	Public limited company
Traded as	MYX: 7081
Industry	Pharmaceuticals Health care
Predecessor	Remedi Pharmaceuticals (1994-1998)[1]
Founded	1994; 28 years ago (1994)
Headquarters	Shah Alam, Selangor, Malaysia
Area served	Worldwide
Key people	Dato' Sri Mohammed Shazalli Ramly, Non-Independent Non-Executive Chairman, Datuk Zulkarnain Md Eusope, Group Managing Director
Products	Prescription drugs, over-the-counter drugs, biopharmaceuticals
Revenue	RM1,970,622,000 (Q2 2021)
Net income	RM36,716,000 (Q2 2021)
Number of employees	3,600
Parent	Boustead Holdings
Subsidiaries	Pharmaniaga Logistics Sdn Bhd Pharmaniaga Marketing Sdn Bhd Pharmaniaga Research Centre Sdn Bhd Pristine Pharma Sdn Bhd Pharmaniaga Biomedical Sdn Bhd Paradigm Industry Sdn Bhd Pharmaniaga Manufacturing Bhd Idaman Pharma Manufacturing Sdn Bhd (Sungai Petani) Idaman Pharma Manufacturing Sdn Bhd (Seri Iskandar) Pharmaniaga LifeScience Sdn Bhd Bio-Collagen Technologies Sdn Bhd PT Millennium Pharmacon International TBK PT Errita Pharma
Website	www.pharmaniaga.com

Pharmaniaga Berhad (Pharmaniaga) is one of Malaysia's largest integrated pharmaceutical groups with a firm focus on protecting the nation via providing accessible and affordable healthcare solutions, with operations in Malaysia and Indonesia.

We are involved in various segments of the pharmaceutical value chain, including research and development, manufacturing of generic drugs and medical devices, logistics and distribution, sales and marketing, as well as community pharmacy.

With over 3,600 employees, Pharmaniaga is home to more than 300 scientists, including researchers, chemists, pharmacologists, formulators, IT engineers, regulatory affairs and clinical affairs specialists.

We have an extensive pharmaceutical logistics and distribution network in Malaysia with four warehouses equipped with pharma-grade cold rooms and deliver drugs as well as medical equipment to almost 10,000 health facilities nationwide.

With seven manufacturing plants, we are capable of producing products in various forms; from oral solids, liquids and creams to small volume injectables. Our product portfolio encompasses a diverse segment of therapeutic areas such as cardiovascular, anti-diabetic, antibiotics, antivirals, over the counter products and nutraceuticals, amongst others. Our high-tech European Union certified plant manufactures fill and finish Sinovac COVID-19 vaccine.

Pharmaniaga’s Indonesia operations include a general pharma manufacturing plant and a public listed pharmaceutical logistics and distribution company with 33 branches throughout the republic.^[2]

History[]

Pharmaniaga was established in 1994 as Remedi Pharmaceuticals.^[1] The company was renamed as Pharmaniaga in August 1998 and is the first healthcare company in Malaysia to be listed in the Main Market of Kuala Lumpur Stock Exchange (now Bursa Malaysia).^[3]

Ownership[]

Pharmaniaga is a public limited company. As at 29 October 2021, Boustead Holdings owns 51.845% of the company, while Lembaga Tabung Angkatan Tentera (LTAT) owns 9.352%. The major owner of Boustead Holdings is itself LTAT.

As at August 2021, the board of directors of Pharmaniaga are Dato' Sri Mohammed Shazalli Ramly who serves as the Non-Independent Non-Executive Chairman, Datuk Zulkarnain Md Eusope as the Group Managing Director and Mohamed Iqbal Abdul Rahman as the Group Deputy Managing Director. The company's Independent Non-Executive Directors are Dato' Dr. Najmil Faiz Mohamed Aris, Datuk Dr. Azhar Ahmad, Zulkifli Jafar, Dr. Abdul Razak Ahmad and Sarah Azreen Abdul Samat while Izaddeen Daud is its Non-Independent Non-Executive Director.

References[]